Innate Pharma has launched a private placement to raise about 18 millions euros

• The private placement will be directed to specialized institutional investors, located mainly in the United-States
• It was launched after market close on November 15

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces today the launch of a private placement to specialized institutional investors, mainly located in the United-States, with the objective of raising about 18 million euros. The private placement was launched after market close on November 15.

Hervé Brailly, CEO, said: “This fundraising responds to the interest expressed by specialist investors with whom we met during the last two years of sustained investor relations effort, notably in the United-States. Innate Pharma has great potential as a pioneer in the very promising field of immuno-oncology and more specifically checkpoint inhibitors. Our programs and partnerships have raised the interest of a highly specialized community of investors and analysts”.

This capital increase will give the Company the means to finance its portfolio of proprietary candidates to 2017.